mRNA horizon
June 11, 2026
19 min
Full
62 of 364
June 11, 2026
mRNA horizon
0:00 / 19:55
Excerpt playback isn’t available for this episode — use the full-episode link.
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
Dr John Campbell Episodes Around June 11, 2026
Episode 62 of 364 — walk the feed in the order it was published.
19:55This episodemRNA horizon
Summary
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
https://news.modernatx.com/news/news-details/2024/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx
May 31, 2024
Moderna, today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345),
an mRNA respiratory syncytial virus (RSV) vaccine,
to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna.
Stéphane Bancel, Chief Executive Officer of Moderna.
The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform
Moderna expects to have mRESVIA available for eligible populations in the U.S. by the 2024/2025 respiratory virus season.
Moderna has filed for mRNA-1345 approval with regulators in multiple markets around the world.
https://www.clinicaltrialsarena.com/news/moderna-races-ahead-in-flu-and-covid-19-combo-vaccine-race-with-phase-iii-win/
Moderna races ahead in flu and Covid-19 combo vaccine race with Phase III win
Moderna injection mRNA-1083
Comprises a seasonal influenza vaccine candidate, mRNA-1010,
and a next-generation Covid-19 vaccine prospect called mRNA-1283.
Moderna announces positive data from a Phase III trial of its mRNA vaccine candidate.
Now, in a Phase III trial (NCT06097273) for mRNA-1083
Moderna
“statistically significantly higher immune responses” compared to existing vaccines on the market.
The trial met its primary endpoints, Moderna said in a 10 June press release.
Immune response was seen across three influenza virus strains (H1N1, H3N2, and B/Victoria) and against SARS-CoV-2.
Although Moderna has not published the full dataset from the Phase III trial,
it plans to present the results in more detail at an upcoming medical conference,
in addition to a submission for publication.
The company said it “will engage with regulators on next steps”.
Other mRNA vaccines in development
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
https://news.modernatx.com/news/news-details/2024/Moderna-Advances-Multiple-Vaccine-Programs-to-Late-Stage-Clinical-Trials/default.aspx
Cytomegalovirus (CMV)
CMVictory is a pivotal Phase 3 trial evaluating mRNA-1647 against primary CMV infection in women 16 to 40 years of age.